ClinicalTrials.gg
RecruitingNCT07862582Updated Nov 12, 2026

RYZ711 Diagnostic Platform Study

A Phase 1/2 interventional study of RYZ711 and PSMA PET/CT in Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate and Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by RayzeBio, Inc.. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by RayzeBio, Inc. (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 12, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 1 of them phase 3. Prostatic Neoplasms · Bristol-Myers Squibb.

Planned enrollment
13th of 29
116 · median 94
Started
2026
the only one that year
Phase 1/2
4 of 30
1 open now
Registered
30th of 30
by date

Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 13th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 30th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
  • Adenocarcinoma of the Prostate
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Biochemical Recurrence (BCR)
  • High-Risk Localized Prostate Cancer

Keywords

  • Prostate Cancer
  • Adenocarcinoma of the Prostate
  • ACP3
  • Acid Phosphatase 3
  • PAP
  • RYZ711
  • PET/CT
  • Positron Emission Tomography
  • Diagnostic Imaging
  • Radiopharmaceutical
  • Radiotracer
  • PSMA
  • Prostate-Specific Membrane Antigen
  • Biochemical Recurrence
  • Radical Prostatectomy
  • Pelvic Lymph Node Dissection
  • PLND
  • mCRPC
  • mHSPC
  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Hormone-Sensitive Prostate Cancer
  • Targeted Imaging
  • Prostate-Specific Antigen
  • PSA
  • Concordance Rate
  • Diagnostic Performance
  • Phase 1
  • Phase 2
  • Basket Study
  • Multicenter Study
  • Gallium-68 / ⁶⁸Ga
  • 68Ga-PSMA-11
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria are eligible for inclusion in the study:

  1. confirmed adenocarcinoma of the prostate
  2. PS ≤ 2
  3. Planned or scheduled PSMA PET/CT scan
  4. Cohort 1: Unfavorable intermediate-risk or higher per NCCN 2026 guidelines, with planned RP and extended PLND within 6 weeks of RYZ711 PET/CT
  5. Cohort 2: Rising PSA after definitive therapy meeting standard BCR criteria (AUA 2026 or Phoenix criteria)
  6. Cohort 3: mHSPC or mCRPC with documented disease progression; candidate for PSMA-targeted radiopharmaceutical therapy

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

  1. \< 60 mL/min, > 470 ms, impaired hepatic function
  2. Neuroendocrine, sarcomatoid, or spindle cell prostate cancer
  3. Non-prostate
  4. Cohort 1: Any prior prostate cancer therapy
  5. Cohort 2: Ongoing or recent ADT (within 3 months prior to Day 1)
  6. Cohort 3: Prior ¹⁷⁷Lu-PSMA therapy within 6 weeks of PSMA PET/CT
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - RYZ711

    High-risk localized prostate cancer planned for RP/PLND

    Drug: RYZ711 · Diagnostic Test: PSMA PET/CT

  • Experimental
    Cohort 2 - RYZ711

    Biochemical recurrence after definitive therapy

    Drug: RYZ711 · Diagnostic Test: PSMA PET/CT

  • Experimental
    Cohort 3 - RYZ711

    Metastatic disease (mHSPC or mCRPC)

    Drug: RYZ711 · Diagnostic Test: PSMA PET/CT

Interventions

  • DrugRYZ711

    RYZ711 PET/CT; PSMA PET/CT

  • Diagnostic testPSMA PET/CT

    RYZ711 PET/CT; PSMA PET/CT

06

What researchers measure

Primary outcomes

  1. Incidence of AEs, SAEs, and Adverse Events of Special Interest (AESIs)

    Incidence of AEs, SAEs, and AESIs including changes in vital signs, clinical laboratory evaluations, 12-lead ECG, and other safety findings

    Time frame: From informed consent up to 3 months post-RYZ711 PET/CT

  2. Concordance Rate of RYZ711 PET/CT Compared with PSMA PET/CT

    The concordance rate is defined as the proportion of subjects with per-region correspondence of at least 1 lesion identified on RYZ711 PET/CT and PSMA PET/CT

    Time frame: Up to 3 months post-RYZ711 PET/CT

07

Study locations

1 of 1 sites recruiting
  • Research Facility
    Omaha, Nebraska 68130, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 14 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Oct 5, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added — first site in United States. Research Facility is now Recruiting
Show site
  • Research Facility · Omaha, United States
across 2 updates, Oct 19, 2026 – Nov 12, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 3 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    Research Facility is now Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 19, 2026
    1 site added — first site in United States
    Show site
    • Research Facility · Omaha, United States
  3. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862582
Lead sponsor
RayzeBio, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 5, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

RayzeBio Clinical Trials
Contact
clinicaltrials@rayzebio.com
+1 619 657 0057
Anthony A Golsorkhi, MD, Study Director, RayzeBio, Inc, MD Study Director
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion